Table 2.
Clozapine-induced hypersalivation.
| Measure of hypersalivation | n (%) |
|---|---|
| Presence of hypersalivation | |
| Yes | 90 (91.8) |
| No | 8 (8.2) |
| NHRS | |
| Absent | 15 (15.3) |
| Minimal (saliva on pillow) | 52 (53.1) |
| Mild (wakes patient once per night) | 15 (15.3) |
| Moderate (wakes patient twice per night) | 9 (9.2) |
| Severe (wakes patient three times or more) | 7 (7.1) |
| DSFS: drooling severity | |
| Nil | 51 (52) |
| Mild drooling (wets lips) | 16 (16.3) |
| Moderate drooling (drool reaches lips and chin) | 13 (13.3) |
| Severe drooling (drool drips onto clothing) | 15 (15.3) |
| Profuse drooling (drool drips onto furniture or objects) | 3 (3.1) |
| DSFS: drooling frequency | |
| No drooling | 51 (52) |
| Occasional drooling | 27 (27.6) |
| Frequent drooling | 11 (11.2) |
| Constant drooling | 9 (9.2) |
| Impact of hypersalivation on quality of life | |
| No effect | 36 (42.4) |
| Minor effect | 33 (38.8) |
| Moderate effect | 7 (8.2) |
| Major effect | 5 (5.9) |
| Profound effect (greatest difficulty in life at present) | 1 (1.2) |
| Perceived awareness of hypersalivation by treating team* | |
| Fully aware | 52 (61.2) |
| Underestimated or minimal awareness | 8 (9.4) |
| Totally unaware | 13 (15.3) |
DSFS, Drooling Severity and Frequency Scale; NHRS, Nocturnal Hypersalivation Rating Scale.
*
Some participants chose not to answer this question (n = 17).